Keros Therapeutics Inc
09/30/2024 | Press release | Distributed by Public on 09/30/2024 06:01
Material Event Form 8 K
Item 8.01 Other Events.
On September 30, 2024, Keros Therapeutics, Inc. (the "Company") announced that it completed enrollment of the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension. A total of 113 patients were enrolled, exceeding the initial target enrollment of 90 patients for the trial. The Company expects to present topline data in the second quarter of 2025.
This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expected timing for data readout for the TROPOS trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize, including those risk factors discussed or referred to in the Company's filings with the SEC, including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.